Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0UR1H
|
|||
| Drug Name |
Peptide analog 54
|
|||
| Synonyms |
PMID26560530-Compound-43
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Company |
DOMINGUEZ, Celia PRIME, Michael MARSTON, Richard BROOKFIELD, Frederick, A. COURTNEY, Stephen, M. MACDONALD, Douglas WITYAK, John YARNOLD, Christopher, John VAIDYA, Darshan
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C27H33ClN4O4
|
|||
| Canonical SMILES |
C=CC(=O)NCCCCC(C(=O)N1CCN(CC1)C2=CC=CC=C2Cl)NC(=O)OCC3=CC=CC=C3
|
|||
| InChI |
1S/C27H33ClN4O4/c1-2-25(33)29-15-9-8-13-23(30-27(35)36-20-21-10-4-3-5-11-21)26(34)32-18-16-31(17-19-32)24-14-7-6-12-22(24)28/h2-7,10-12,14,23H,1,8-9,13,15-20H2,(H,29,33)(H,30,35)/t23-/m0/s1
|
|||
| InChIKey |
KYVYJVRZPFRADU-QHCPKHFHSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Tissue transglutaminase (TG2) | Target Info | Inhibitor | [1] |
| Target's Patent Info | Tissue transglutaminase (TG2) | Target's Patent Info | [1] | |
| KEGG Pathway | Huntington's disease | |||
| Pathway Interaction Database | Beta1 integrin cell surface interactions | |||
| Thromboxane A2 receptor signaling | ||||
| Alpha9 beta1 integrin signaling events | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.